AbbVie says Phase 3 AFFIRM trial shows subcutaneous Skyrizi lifts endoscopic remission in Crohn’s disease patients
AbbVie released new Phase 3 AFFIRM results for subcutaneous Skyrizi in moderate-to-severe Crohn’s disease, presented at ACG 2026. Data showed improved intestinal healing outcomes versus placebo, supporting deeper disease control with a self-administered induction regimen. Findings build on previously presented week 12